Table 5Duloxetine compared with pregabalin

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionSummary effect size (95% confidence interval)High, Moderate, Low, Insufficient
Outcome 1
Pain: Difference in mean difference
Duloxetine 3, N=1081
Pregabalin 4, N= 2774
RCT/FairConsistentIndirectPrecise−0.27 (−0.68 to −0.15)Low
Outcome 2
50% Response in reduction of pain: Ratio of RR
Duloxetine 3, N=1081
Pregabalin 3, N=2026
RCT/fairConsistentIndirectPrecise0.91 (0.65 to 1.28)Low
Outcome 3
Fibromyalgia Impact Questionnaire: Difference in mean difference
Duloxetine 3, N=1081
Pregabalin 2, N=1498
RCT/fairConsistentIndirectImprecise−2.97 (−6.40 to 0.46)Low
Outcome 4
Fatigue: Difference in standardized mean difference
Duloxetine 2, N=727
Pregabalin 2, 1279
RCT/fairConsistentIndirectPrecise0.13 (−0.12 to 0.38)Low
Outcome 5
Overall withdrawal: Ratio of RR (95% CI)
Duloxetine 3, N=1081
Pregabalin 4, N=2774
RCT/FairConsistentIndirectPrecise0.84 (0.64 to 1.10)Low
Outcome 6
Overall adverse events: Ratio of RR (95% CI)
Duloxetine 2, N=561
Pregabalin 4, N=2774
RCT/FairConsistentIndirectPrecise0.99 (0.90 to 1.09)Low
Outcome 7
Withdrawal due to adverse events: Ratio of RR (95% CI)
Duloxetine 3, N=1081
Pregabalin 4, N=2774
RCT/FairConsistentIndirectImprecise0.83 (0.56 to 1.24)Low

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Drugs for Fibromyalgia
Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet].
Smith B, Peterson K, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.